Encyclopedia entry
Cerebrolysin
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-26
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · Cerebrolysin
Cerebrolysin is a porcine brain-derived preparation containing a complex mixture of low-molecular-weight neuropeptides and free amino acids. It has been used clinically in parts of Eastern Europe for decades for acute ischaemic stroke, vascular dementia, and Alzheimer disease. It is a prescription-only medicine in countries such as Russia, Austria, Germany, and Poland. It holds no UK or US marketing authorisation. Larger Western randomised controlled trials and Cochrane reviews have reported mixed or modest effects with substantial heterogeneity between studies. PeptideClear is gathering UK information on Cerebrolysin; in the UK regulatory context this is a research-only compound.
Mechanism of action
How Cerebrolysin works
Cerebrolysin is described by its manufacturer as a neurotrophic preparation acting in a manner proposed to resemble endogenous nerve growth factors. In preclinical models it has been reported to promote neuronal survival, support neurogenesis, and modulate amyloid pathology. Authors typically describe a BDNF-like and NGF-like signalling profile rather than binding to a single named receptor. Because the preparation is a heterogeneous mixture rather than a single defined molecule, the mechanistic literature describes effects of the mixture as a whole.
Source: PubMed search: Cerebrolysin mechanism (neurotrophic and neurotrophin signalling literature)
What the literature shows
The Cerebrolysin literature splits geographically. Eastern European and Asian clinical studies, often single-centre and sometimes open-label, have generally reported favourable outcomes across stroke, vascular dementia, and Alzheimer indications. Larger Western multi-centre randomised controlled trials and the Cochrane systematic reviews have reported mixed or modest effects, with high heterogeneity between studies and concerns about risk of bias in parts of the historical literature. The evidence base is contested rather than settled.
- · CASTA (Cerebrolysin Acute Stroke Treatment in Asia) randomised trial in acute ischaemic stroke reporting modest functional outcome differences without meeting all primary endpoints.
- · CARS (Cerebrolysin and Recovery After Stroke) trials reporting motor recovery differences in selected post-stroke rehabilitation populations.
- · Cochrane systematic reviews concluding the evidence base for stroke and dementia indications is heterogeneous and of variable methodological quality.
- · Eastern European registry data and observational cohorts describing decades of routine clinical use.
- · Preclinical rodent and cell-culture work describing BDNF-like and NGF-like signalling activity of the mixture.
- · No US Food and Drug Administration approval and no UK MHRA marketing authorisation. Licensed as a prescription medicine in Russia, Austria, Germany, Poland, and several other jurisdictions.
Related compounds: Semax (see Semax encyclopedia entry) and Selank (see Selank encyclopedia entry) sit in the adjacent Russian-origin neuropeptide research literature, with different proposed mechanisms and similarly limited Western RCT data.
UK regulatory status
Cerebrolysin is a prescription-only medicine in several countries (including Russia, Austria, Germany, and Poland). In the UK it has no MHRA marketing authorisation and no licensed route of supply. It is not a controlled drug under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016, but the absence of a UK licence means any UK supply route sits outside the regulated medicines tier and any therapeutic claim made about it in the UK creates an unlicensed medicinal product position.
- · Not a controlled drug under the Misuse of Drugs Act 1971.
- · Not scheduled under the Psychoactive Substances Act 2016.
- · No UK marketing authorisation as a medicine.
- · No US Food and Drug Administration approval.
- · Prescription-only medicine in Russia, Austria, Germany, Poland, and several other jurisdictions where it is licensed for stroke and cognitive indications.
- · In the UK, any therapeutic claim creates an unlicensed medicinal product position under the Human Medicines Regulations 2012.
- · Frame any UK discussion as research compound rather than treatment option.
Risks and unknowns
What the literature does not yet show about Cerebrolysin
Known concerns
- No UK marketing authorisation. The MHRA has not assessed UK supply chains for purity, sterility, or composition consistency.
- Porcine brain-derived biological preparation. Sourcing, processing, and batch-to-batch consistency are not subject to UK regulatory oversight.
- Western RCT evidence is mixed. Effect sizes reported in larger trials are modest and confidence intervals often cross the null.
- Used as an injectable in licensed jurisdictions. Sterile injection technique, contamination risk, and infection control sit entirely outside any UK-licensed supply chain.
- Any UK channel marketing it for stroke, dementia, or cognitive indications creates immediate unlicensed medicinal product exposure under the Human Medicines Regulations 2012.
Open questions in the literature
- Long-term safety in healthy adults outside licensed clinical indications has not been characterised in modern ICH-GCP trials.
- The active components within the heterogeneous mixture responsible for any reported clinical effect have not been definitively identified.
- Whether the favourable Eastern European clinical outcomes reflect real efficacy, methodological differences, or publication patterns remains contested in the systematic review literature.
- Pharmacokinetics of a complex peptide mixture across the blood-brain barrier are difficult to characterise and not well established in the Western literature.
Regulatory note
Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation. Prescription-only medicine in several other jurisdictions including Russia, Austria, Germany, and Poland. In the UK, any therapeutic claim creates an unlicensed medicinal product position under the Human Medicines Regulations 2012.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Where to learn more
- · PubMed search: Cerebrolysin returns several hundred papers across stroke, dementia, and traumatic brain injury indications.
- · PubMed: Cerebrolysin stroke for the CASTA and CARS randomised trial literature.
- · PubMed: Cerebrolysin Alzheimer for the dementia indication literature.
- · Cochrane Library: Cerebrolysin reviews for the systematic-review assessment of the evidence base.
- · Related compounds: Semax and Selank for the adjacent Russian-origin neuropeptide literature.
- · UK retailer purity comparison: research peptides UK retailers.
Frequently asked questions
Is Cerebrolysin legal in the UK?
What does the human evidence show for Cerebrolysin?
What is the regulatory status of Cerebrolysin in the UK?
What forms does Cerebrolysin come in?
Where can I learn more about Cerebrolysin?
UK retailer coverage
PeptideClear does not currently maintain UK retailer data for Cerebrolysin. Cerebrolysin is a prescription medicine in several other jurisdictions and has no UK marketing authorisation. The UK research peptide retailer directory covers the broader supply landscape for comparison.
UK research peptide retailersClinical evidence record
Read the clinical evidence record for Cerebrolysin
Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.
Popular on PeptideClear
Ready to buy
Buy Cerebrolysin in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.